secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karuna Therapeutics, Inc. (—)
CIK:        0001771917
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-037552
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karuna reports Q2 net loss $103.2M; CFO transition, NDA for KarXT on track
--------------------------------------------------------------------------

- Net loss $103.2M vs $64.9M a year ago; R&D $92.5M, G&A $27.4M.
- Cash $1.4B as of June 30, 2023, sufficient to fund operations through 2026.
- CFO Troy Ignelzi to depart Sept 29, 2023; succeeded by Jason Brown (SVP Finance).
- Jason Brown receives base salary $505,000, target bonus 45%, equity grants $1.6M total.
- NDA submission for KarXT in schizophrenia on track for Q3 2023; potential launch H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771917/000095017023037552/0000950170-23-037552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771917/000095017023037552/krtx-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer